Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.47 |
| ▸ | CA2 | P00918 | 9/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 5/20 | 0.39 |
| ▸ | JAK1 | P23458 | 5/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25171837 | 0.83 | JAK2 (0.39) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL18052593 | 0.83 | JAK2 (0.37) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL16611316 | 0.75 | CA1 (0.42) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL16611375 | 0.75 | JAK2 (0.33) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL6013977 | 0.64 | PTGS2 (0.61) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL16610875 | 0.64 | JAK2 (0.52) | PTGS2JAK2JAK1 | |
| SCHEMBL6013987 | 0.64 | PTGS2 (0.60) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL6959431 | 0.64 | CA1 (0.47) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL3100354 | 0.64 | PTGS2 (0.54) | CA1CA2CA9CA12PTGS2 | |
| SCHEMBL6013942 | 0.64 | PTGS2 (0.60) | CA1CA2CA9CA12PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | CA1 2704/4885CA2 1618/4885CA9 1560/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | CA1 2704/4885CA2 1618/4885CA9 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.